Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: October 6, 2022

Patent: 4,588,585

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 4,588,585
Title: Human recombinant cysteine depleted interferon-.beta. muteins
Abstract:Muteins of biologically active proteins such as IFN-.beta. and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins are made via bacterial expression of mutant genes that encode the muteins that have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.
Inventor(s): Mark; David F. (Danville, CA), Lin; Leo S. (Fremont, CA), Yu Lu; Shi-Da (Oakland, CA)
Assignee: Cetus Corporation (Emeryville, CA)
Application Number:06/655,897
Patent Claims:see list of patent claims

Details for Patent 4,588,585

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bayer Healthcare Pharmaceuticals Inc. BETASERON interferon beta-1b For Injection 103471 07/23/1993 See Plans and Pricing 2003-05-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 4,588,585

Country Patent Number Estimated Expiration
South Africa 837789 See Plans and Pricing
United States of America RE33653 See Plans and Pricing
United States of America 4853332 See Plans and Pricing
United States of America 4737462 See Plans and Pricing
United States of America 4518584 See Plans and Pricing
Portugal 77512 See Plans and Pricing
Philippines 23702 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.